Markers of Prognosis and Response to Therapy in Patients With Metastatic Brain Tumors Undergoing Stereotactic Radiosurgery (SRS)

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01908179

Enrollment

100

Registered

2013-07-25

Start date

2013-01-31

Completion date

Unknown

Last updated

2013-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Brain Tumor

Keywords

Sterotactic Radiosurgery

Brief summary

This registry study will evaluate patients with metastatic brain tumors undergoing, or having undergone, stereotactic radiosurgery (SRS) at Swedish Medical Center. Clinical outcomes will be evaluated at the 3, 6 and 12-month time points. Clinical data, SRS treatment data, and imaging data (including anatomic and advanced imaging sequences obtained prior to and serially following SRS) will be archived in an online informatics platform, specifically a metastatic brain tumor registry known as the Comprehensive Neuro-oncology Data Repository for Metastatic Tumors (CONDR - Mets).

Interventions

None listed

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

19 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Adult patients (\>18 yo) with a pathological diagnosis of metastatic brain cancer * Participants must have \>4 tumors felt to require stereotactic radiosurgery * Karnofsky scale of \> 70 at the time of initial treatment * Age \< 80

Exclusion criteria

* Karnofsky scale \<70 * Age \> 80 * Inability to undergo MR imaging studies

Design outcomes

Primary

Measure	Time frame
Quantitative measures of overall tumor volume will be performed for each subject at the time of SRS	At the time of SRS
Quantitative measures of tumor number will be performed for each subject at the time of SRS	At the time of SRS
Overall survival will be measured for each subject (in weeks from SRS to death)	Post-SRS

Secondary

Measure	Time frame
Measures of ADC, rCBV, MTT and ktrans will be performed for each treated tumor at treatment and at 6 months following SRS	6 months post SRS
Time to progression (in weeks) will be measured for each treated tumor	Post-SRS
Diagnosis of progression or radiation necrosis (made on clinical reflection at study's end) will be determined for tumors where diagnosis is in question at 6 and 12 months after SRS	12 months post-SRS

Countries

United States

Contacts

Primary ContactTracie Granger

tracie.granger@swedish.org206-215-2466

Outcome results